Behandlung der chronischen peripheren arteriellen Verschlußkrankheit mit physikalischem Training und Rökan—Ergebnisse einer placebokontrollierten Doppelblindstudie

Bulling, B.; Bary, S. v.

doi:10.1007/978-3-642-77428-7_2

Cited by 1 publication

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These products, often sold as memory enhancers, are used therapeutically for the symptomatic treatment of mild to moderate age‐associated memory impairment (AAMI) and dementia, including primary degenerative dementia, vascular (multi‐infarct) dementia, and Alzheimer's disease 10,14–25 . Standardized extracts have also been shown to be effective for the symptomatic treatment (improvement of pain‐free walking distance) of peripheral arterial occlusive disease, such as intermittent claudication 10,14,26–35 . Furthermore, there is some evidence that Gingko biloba extracts may be of some benefit for the treatment of inner ear disorders, such as acoustic trauma, hearing loss, tinnitus, and vertigo of vascular and involutive origin 10,36–50 .…”

Section: Therapeutic Usesmentioning

confidence: 99%

“…The efficacy of a standardized GBE ( EGb 761) for the treatment of intermittent claudication ( peripheral arterial occlusive disease Fontaine stage II ) has been assessed in at least 20 clinical trials 1,14,26–34 . A review of 15 earlier clinical trials (published prior to 1991) 14 determined that only 2 of the studies employed acceptable methodology 26,27 .…”

Section: Clinical Pharmacologymentioning

confidence: 99%

“…In human studies, GBE treatment has been shown to improve global and local cerebral blood flow and skin perfusion and microcirculation, 6–68 to protect against hypoxia, 69 to improve blood rheology, including inhibition of platelet aggregation, 64,66,70–72 to improve tissue metabolism, 68,73 and to reduce capillary permeability 74…”

Section: Mechanism Of Actionmentioning

confidence: 99%

See 2 more Smart Citations

Ginkgo Biloba: A Review of Quality, Safety, and Efficacy

Mahady

2001

Nutrition in Clinical Care

View full text Add to dashboard Cite

Results from randomized, controlled clinical trials support the use of standardized leaf extracts of Ginkgo biloba for the symptomatic treatment of age‐associated memory impairment, dementia (including Alzheimer's disease), and intermittent claudication. Product selection is extremely important, as much of the published safety and efficacy data are based on 2 standardized extracts, both available in the US. The recommended dose of a Ginkgo biloba leaf extract (standardized to contain 24–26% flavonoid glycosides, 5–7% terpene lactones, and less than 5 parts per million ginkgolic acids) is 40 mg to 60 mg, 3 to 4 times a day. Daily administration of the extract for at least 4 to 6 weeks is required before the full therapeutic effects may be observed. While there are no known contraindications, due to potential platelet‐activating factor antagonism and inhibition of platelet aggregation, Ginkgo extracts should be used cautiously in patients receiving anticoagulant or antiplatelet therapy or having bleeding disorders. A number of bleeding episodes due to co‐administration of aspirin or warfarin have been reported. Other adverse reactions, such as nausea, vomiting, headaches, and dizziness have also been observed in clinical trials. Administration of Ginkgo biloba preparations to children or during pregnancy or nursing is not currently recommended.

show abstract

Section: Therapeutic Usesmentioning

confidence: 99%

Section: Clinical Pharmacologymentioning

confidence: 99%